Sulfonylureas may increase risk of death in type 2 diabetes patients

09/26/2013 | U.S. News & World Report

British researchers found type 2 diabetes patients who used sulfonylureas as an initial treatment had a 58% higher risk of all-cause mortality compared with those who were on metformin monotherapy. While more data are needed, the results suggest using sulfonylureas as first-line monotherapy "should be reconsidered," researchers reported at the European Association for the Study of Diabetes meeting.

View Full Article in:

U.S. News & World Report

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN